Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

A pill from Eli Lilly helped patients improve their blood sugar and shed weight, results that could propel the ...

Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the ...

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...